Cao Xianglong, Cui Jian, Yu Tao, Li ZiJian, Zhao Gang
Department of Gastrointestinal Surgery, National Center of Gerontology, Beijing Hospital, Beijing, China.
Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Front Oncol. 2020 Aug 18;10:1459. doi: 10.3389/fonc.2020.01459. eCollection 2020.
Nutritional status, systemic inflammation, and coagulation mechanism are closely related to tumor progression. Herein, we examined the role of fibrinogen-to-albumin ratio index (FARI) in the prognosis of gastrointestinal stromal tumors (GISTs) and developed a novel nomogram predicting recurrence-free survival (RFS). We retrospectively analyzed data from 357 GIST patients admitted at the gastrointestinal surgery of the Beijing Hospital from January 2008 to January 2018 and underwent curative resection. FARI was calculated as fibrinogen level (g/L) /albumin level (g/L). The cutoff point of FARI was set using the point with the largest Youden index on the receiver operating characteristic curve with the 5-years recurrence-free survival as an endpoint. We used the Kaplan-Meier approach and multivariable Cox regression model to study the impact of FARI on recurrence-free survival. Finally, we developed a nomogram based on tumor size, location, mitotic index, and FARI to predict RFS. The nomogram was assessed by calculating concordance probabilities and testing calibration of predicted RFS with observed RFS. Concordance probabilities were also compared with the National Institute of Health (NIH) risk classification system. The ROC curve revealed that the best cutoff point of the FARI was set as 0.08. The patients were classified into the FARI-high (≥0.08) and FARI-low (<0.08) groups. FARI was significantly associated with age, size of the tumor, NIH risk category, and Mitotic Index (all < 0.05). FARI was weakly associated with NLR and PLR. FARI and PNI had a weak negative association. Multivariate analysis showed that the NIH risk category and FARI were independent prognostic predictors for worse outcomes concerning RFS in GIST patients. In the high-risk subgroup, patients with low FARI also had a more prolonged RFS than patients with high FARI ( < 0.05). The nomogram had a concordance probability of 0.802 (SE 0.025). Nomogram predictions were well-calibrated. Concordance probabilities of the nomogram were better than NIH risk classification system [0.802 [0.025] vs. 0.737 [0.024], < 0.01]. We established that preoperative FARI is a novel serum biomarker to predict the prognosis after surgical resection of GISTs. The nomogram incorporating FARI could be used to help the decision-making of clinical treatment.
营养状况、全身炎症和凝血机制与肿瘤进展密切相关。在此,我们研究了纤维蛋白原与白蛋白比值指数(FARI)在胃肠道间质瘤(GIST)预后中的作用,并开发了一种预测无复发生存期(RFS)的新型列线图。我们回顾性分析了2008年1月至2018年1月在北京医院胃肠外科住院并接受根治性切除术的357例GIST患者的数据。FARI计算为纤维蛋白原水平(g/L)/白蛋白水平(g/L)。以5年无复发生存期为终点,使用受试者工作特征曲线上约登指数最大的点来设定FARI的截断点。我们使用Kaplan-Meier法和多变量Cox回归模型来研究FARI对无复发生存期的影响。最后,我们基于肿瘤大小、位置、有丝分裂指数和FARI开发了一种列线图来预测RFS。通过计算一致性概率并检验预测的RFS与观察到的RFS的校准情况来评估列线图。还将一致性概率与美国国立卫生研究院(NIH)风险分类系统进行了比较。ROC曲线显示FARI的最佳截断点设定为0.08。患者被分为FARI高(≥0.08)组和FARI低(<0.08)组。FARI与年龄、肿瘤大小、NIH风险类别和有丝分裂指数显著相关(均<0.05)。FARI与中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR)弱相关。FARI与预后营养指数(PNI)有弱负相关。多变量分析表明,NIH风险类别和FARI是GIST患者RFS较差结局的独立预后预测因素。在高危亚组中,FARI低的患者的RFS也比FARI高的患者更长(<0.05)。列线图的一致性概率为0.802(标准误0.025)。列线图预测校准良好。列线图的一致性概率优于NIH风险分类系统[0.802(0.025)对0.737(0.024),<0.01]。我们确定术前FARI是一种预测GIST手术切除后预后的新型血清生物标志物。纳入FARI的列线图可用于帮助临床治疗决策。